Periowave(TM) Gum Disease Therapy: Positive Results From Meta-analysis



    VANCOUVER, Sept. 10 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM:
OBP), a medical technology company, today announced results of a meta-analysis
(statistical review of pooled clinical trial data) of its Periowave(TM)
Photodynamic Disinfection System in the treatment of gum disease. The analysis
covered three trials enrolling a total of 126 patients at four clinical
centers over the past two years. Among other data, the meta-analysis found
that Periowave(TM) used in a re-treatment protocol (six weeks apart) produced
2.3 times more clinically relevant (2+ mm) pocket depth reductions than the
gold standard of scaling and root planing (SRP) alone (p(less than)0.0001).
    Studies included a trial at an independent clinic in Everett, WA where
clinically and statistically significant endpoints were achieved; a two-center
study conducted by Loma Linda University where clinically and statistically
significant endpoints were achieved and a study conducted by University of
British Columbia where it was found that the protocol allowed for too few
patients meeting inclusion criteria to be recruited. Patients who did meet
inclusion criteria were included in the meta-analysis. No treatment-related
adverse events were reported at any center. Endpoints included pocket depth,
clinical attachment level and bleeding on probing.
    The meta-analysis results supported prior findings, demonstrating that
Periowave(TM) was safe and effective in producing statistically and clinically
relevant improvements in periodontal pocket depth compared to scaling and root
planing. Periowave(TM) produced more than double the number of large (2+ mm)
pocket depth reductions than scaling and root planing alone (p(less
than)0.0001). The results were achieved across studies that incorporated
different ethnic groups, smoking status, treatment protocols and laser power
levels.
    "These positive meta-analysis results will be integrated into our FDA
submission," said Carolyn Cross, CEO and President of Ondine Biopharma.
"Periowave(TM) has now been successfully tested in standard recall patients,
patients with advanced disease, patients undergoing re-treatment protocols and
patients with recurrent disease. In addition, Periowave(TM) has already been
extensively deployed in the dental clinic following its approval in Canada and
the European Union, with several thousand patients treated to date.
Periowave(TM) has proven to be a safe and effective adjunct to SRP in many
patients, irrespective of demographics, smoking status or nature of the
disease".

    About Periowave(TM) and Photodisinfection
    -----------------------------------------
    Periowave(TM) is a Photodisinfection system developed by Ondine that
utilizes low-intensity lasers and wavelength-specific, light-activated
photosensitive compounds to specifically target and destroy microbial
pathogens and reduce the symptoms of disease. The compounds are topically
applied and lasers of appropriate wavelength and intensity are used to
disinfect the treatment site.

    About Ondine Biopharma Corporation
    ----------------------------------
    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is headquartered in Vancouver, British
Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and
an international office in St. Michael, Barbados. For additional information,
please visit the Company's website at: www.ondinebiopharma.com

    Forward-Looking Statements:

    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

    The TSX Exchange has not reviewed and does not accept responsibility for
    the adequacy or accuracy of this release





For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com; Nominated
Adviser, Neil Johnson, Ryan Gaffney, Canaccord Adams Ltd, +44(0)20 7050 6500

Organization Profile

ONDINE BIOPHARMA CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890